The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Health-care companies ticked up, but lost ground during a generally positive week for the stock market amid fears about the implications of a tight presidential race for health-care regulation.

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...